Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, for Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects in trials, and the potential for halting recruitment and dosing due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - Investors who purchased Sarepta securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to the safety of its product ELEVIDYS, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by August 25, 2025 [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that Sarepta and its executives made false or misleading statements regarding the safety of ELEVIDYS, failing to disclose significant safety risks and adverse events associated with the treatment [5]. - The firm encourages investors who suffered losses exceeding $100,000 in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1][3]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [6]. - On April 4, 2025, after disclosing that EU authorities requested a review of the death, the stock price dropped by $4.18 per share, or 7.13%, closing at $54.43 [8]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [10]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [11].

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Why is Sarepta being Investigated? Sarepta is a biopharmaceutical company focused on developing treatment ...

Core Viewpoint - The FDA is investigating the risk of acute liver failure associated with Sarepta Therapeutics' Elevidys treatment, which has resulted in serious outcomes including hospitalization and death [1][2]. Group 1: FDA Investigation - The FDA has received two reports of fatal acute liver failure in non-ambulatory pediatric male patients with Duchenne Muscular Dystrophy (DMD) following treatment with Elevidys [2]. - The agency is evaluating the need for further regulatory action based on these reports [1]. Group 2: Patient Outcomes - In the reported cases, patients exhibited elevated transaminases and were hospitalized within two months after receiving Elevidys [3]. - Both fatalities appear to be directly related to the treatment with Elevidys [2]. Group 3: Analyst Reactions - HC Wainwright has reiterated a Sell rating for Sarepta, maintaining a price forecast of $10, citing the likelihood of the FDA requiring updated warnings regarding liver failure or death [4]. - The worst-case scenario for Sarepta would involve the FDA mandating the withdrawal of Elevidys from the U.S. market [4][5]. Group 4: Company Valuation - If Elevidys were to be withdrawn, analysts believe there would be little intrinsic value remaining in Sarepta [5]. - The skepticism from FDA officials regarding the initial approval of Elevidys suggests potential challenges for the company's continued marketing efforts [6]. Group 5: Stock Performance - Following the news, Sarepta's stock (SRPT) has seen a decline of approximately 9.96%, trading at $17.09 [6].

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Why is Sarepta being Investigated? Sarepta is a biopharmaceutical company focused on developing treatment ...

Core Viewpoint - Sarepta Therapeutics, Inc. is under investigation for potential violations of federal securities laws related to the safety profile of its product Elevidys, which has been linked to fatal acute liver failure in patients [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [2]. Product Safety Concerns - The company has previously emphasized the safety of Elevidys, claiming that its benefits outweigh the risks. However, it has been revealed that Elevidys can cause fatal acute liver failure in some patients [2]. Stock Performance - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [3]. - After a second patient death was reported on June 15, 2025, Sarepta's stock fell by $15.24, or more than 42%, from $36.18 to $20.94 per share [3]. Legal Implications - Investors in Sarepta may have legal options available to them, as indicated by the investigation and the potential for class action lawsuits [4].

Core Insights - Sarepta Therapeutics provided a safety update on Elevidys, the only approved gene therapy for Duchenne muscular dystrophy, following a second case of acute liver failure resulting in death [1] - Investor hesitancy is attributed to uncertainty regarding the number of non-ambulatory patients treated and their risk of developing acute liver failure [2] - Analyst Sami Corwin downgraded Sarepta from Outperform to Market Perform due to concerns over revenue estimates and competition from other gene therapies [2][3] Company Developments - The company is taking steps to strengthen the safety profile of Elevidys in non-ambulatory patients after the reported cases of acute liver failure [1] - There is a growing concern that the penetration of the non-ambulatory population may not meet previous peak revenue estimates, impacting future revenue potential [3] - Sarepta's stock price decreased by 3.18% to $20.11, reflecting investor concerns over the safety profile and revenue outlook [4] Market Context - The potential entry of other AAV gene therapies for Duchenne muscular dystrophy by 2027 could further impact Sarepta's peak revenue estimates [3] - Early clinical data from competitors suggests they may have a safer profile with fewer liver-related side effects, increasing competitive pressure on Sarepta [3] - Despite expected strong interest among commercial ambulatory patients, the uncertainty surrounding non-ambulatory patient treatment is seen as a deterrent for investors [4]

Core Viewpoint - Sarepta Therapeutics, Inc. is under investigation for potential violations of federal securities laws related to the safety profile of its product Elevidys, which has been linked to fatal acute liver failure in patients [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [2]. Incident Timeline - On March 18, 2025, Sarepta announced the death of a patient treated with Elevidys due to acute liver failure, resulting in a stock price drop of $27.81, or over 27%, from $101.35 to $73.54 per share [3]. - Following a second patient death on June 15, 2025, Sarepta suspended certain shipments of Elevidys and paused dosing in an ongoing clinical trial, leading to a further stock decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [3]. Legal Implications - Investors in Sarepta may have legal options available and are encouraged to submit their information to the investigating law firm, Bleichmar Fonti & Auld LLP, which operates on a contingency fee basis [4][5]. Law Firm Background - Bleichmar Fonti & Auld LLP is a prominent international law firm specializing in securities class actions and shareholder litigation, recognized for recovering significant amounts for clients in past cases [5].

Core Viewpoint - Sarepta Therapeutics faces significant challenges following the second death linked to its DMD treatment ELEVIDYS, leading to a suspension of shipments for non-ambulatory patients and a drastic drop in stock price [1][2][4]. Group 1: Sarepta Therapeutics - The recent death of a patient due to acute liver failure after treatment with ELEVIDYS marks a second tragic incident, raising serious concerns about the safety of the drug [1]. - Following the incident, Sarepta suspended shipments of ELEVIDYS for non-ambulatory patients and withdrew its revenue guidance, resulting in a stock price decline of over 42% [2][4]. - ELEVIDYS accounted for 61% of Sarepta's total revenue of $612 million last quarter, with sales growth of 180%, making the suspension a critical blow to the company's financial outlook [5]. - Despite the suspension, only 15% of ELEVIDYS patients have been non-ambulatory, allowing Sarepta to continue selling to the majority of its patient base [6]. - The company is working on an enhanced regimen to mitigate the risk of liver failure, pending FDA approval, with hopes to provide guidance during its Q2 earnings call [7][8]. Group 2: Solid Biosciences - Solid Biosciences, developing a potentially safer alternative to ELEVIDYS called STG-003, saw its shares rise over 11% following Sarepta's news, indicating investor confidence in its prospects [3][10]. - STG-003 has shown high efficacy in early-stage trials, with the highest average microdystrophin expression among DMD gene therapies to date, positioning it as a strong contender in the market [10]. - Liver safety concerns are prevalent in gene therapies, with ELEVIDYS causing elevated liver enzymes in about 30% of patients, while STG-003 appears to be less damaging to the liver [11]. - Solid plans to meet with the FDA in Q4 2025 to discuss the potential for accelerated approval of STG-003, which could expedite its entry into the market [13].

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Why is Sarepta being Investigated? Sarepta is a biopharmaceutical company focused on developing treatment ...